Sigyn Therapeutics™ to Present at Tomorrow’s Emerging Growth Conference
March 05, 2024 09:00 ET
|
Sigyn Therapeutics, Inc.
Live Online Presentation Scheduled at 12 pm EST on March 6th SAN DIEGO, CA, March 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn Therapeutics” or the “Company”)...
Sigyn Therapeutics Announces Appointment of Jerry DeCiccio as Chief Financial Officer
December 12, 2023 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today...
Sigyn Therapeutics™ Discloses PCT Patent Submission to Enhance Chemotherapy Delivery and Reduce Cancer Treatment Toxicity
October 04, 2023 08:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB: SIGY), a development-stage medical technology company, today...
Sigyn Therapeutics to Present at Tomorrow’s Emerging Growth Conference
August 08, 2023 10:30 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, Aug. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (“Sigyn” or the “Company”) (OTCQB:SIGY), a medical technology company that creates blood purification...
Sigyn Therapeutics™ Appoints H. David Humes, MD to Its Scientific Advisory Board
March 15, 2022 09:00 ET
|
Sigyn Therapeutics, Inc.
SAN DIEGO, CA, March 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated...